MAP2K6 (Ab-207) Antibody

What is MAP2K6 (Ab-207) Antibody and what specific phosphorylation site does it detect?

MAP2K6 (Ab-207) Antibody is a rabbit polyclonal antibody specifically designed to detect the phosphorylation of mitogen-activated protein kinase kinase 6 (MEK6/MAP2K6) at serine 207 (Ser207). This antibody recognizes a protein with an observed molecular weight of 35-37 kDa in human samples . Importantly, the antibody also cross-reacts with phosphorylated MEK3 at serine 218 (Ser218) due to sequence homology between these related kinases . This dual reactivity should be considered when designing experiments and interpreting results.

What is the biological significance of MEK6 phosphorylation at Ser207?

Phosphorylation of MEK6 at Ser207 (along with Thr211) by upstream MAP3Ks is a critical activation mechanism that enables MEK6 to phosphorylate and activate downstream p38 MAP kinases . This activation is essential for cellular responses to inflammatory cytokines and environmental stressors. The phosphorylation state of MEK6 serves as an indicator of pathway activation and can be monitored to assess stress response mechanisms. Recent research indicates that MEK6 activity may play a protective role against arterial rupture in vascular Ehlers-Danlos syndrome (vEDS), highlighting its significance in maintaining vascular integrity .

How does MAP2K6 function within the MAPK signaling cascade?

MAP2K6 (also known as MKK6) functions as one of the two primary upstream activators of the p38 family of kinases (p38α, p38β, p38γ, and p38δ) . Following its own activation through phosphorylation at Ser207 and Thr211, MEK6 catalyzes the dual phosphorylation of p38 MAPK at Thr180 and Tyr182 residues . This dual phosphorylation occurs through a partially processive mechanism where monophosphorylated intermediates can either dissociate or proceed to complete phosphorylation, with a preference for phosphorylating Tyr182 approximately four times faster than Thr180 .

What are the optimal conditions for using MAP2K6 (Ab-207) Antibody in Western blot experiments?

For Western blot applications, the recommended dilution range for MAP2K6 (Ab-207) Antibody is 1:1000-1:6000 . Optimal dilution should be determined empirically for each experimental system. The antibody has been validated to detect phosphorylated MEK6 in multiple human cell lines, including UV-treated HEK-293 cells, untreated HEK-293 cells, HeLa cells, and anisomycin-treated HeLa cells . When preparing samples, it is advisable to include phosphatase inhibitors in lysis buffers to preserve phosphorylation states. For storage, the antibody should be kept at -20°C in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3), where it remains stable for one year after shipment .

What treatments can be used to induce MEK6 phosphorylation for positive controls?

Based on the validation data, several treatments can effectively induce MEK6 phosphorylation to serve as positive controls:

These treatments trigger the MAP3K-MAP2K-MAPK signaling cascade, resulting in phosphorylation of MEK6 at Ser207 .

How can I differentiate between phosphorylated MEK6 (Ser207) and MEK3 (Ser218) in my samples?

Differentiating between phosphorylated MEK6 (Ser207) and MEK3 (Ser218) presents a technical challenge due to the antibody's cross-reactivity . Several approaches can help distinguish between these signals:

• Use MEK6-specific or MEK3-specific siRNA/shRNA knockdowns as controls to identify which band corresponds to which protein.

• Employ MEK6-/- or MEK3-/- cell lines or tissues, when available, to confirm specificity.

• Perform immunoprecipitation with isoform-specific antibodies followed by Western blotting with the phospho-specific antibody.

• Use recombinant MEK6 and MEK3 proteins as standards to identify their respective migration patterns.

• Couple Western blot analysis with mass spectrometry to definitively identify phosphorylated peptides.

The observed molecular weight for phosphorylated MEK6 is 35-37 kDa, which may help distinguish it from MEK3 if there is sufficient separation on the gel .

How can MAP2K6 (Ab-207) Antibody be used to study the dynamics of p38 MAPK pathway activation?

MAP2K6 (Ab-207) Antibody serves as a valuable tool for investigating the temporal dynamics of p38 MAPK pathway activation. Researchers can design time-course experiments following various stimuli to monitor the sequential phosphorylation events from MAP3Ks to MEK6 to p38 MAPKs. By combining this antibody with antibodies against phosphorylated p38 (Thr180/Tyr182), researchers can establish the kinetics of signal transmission through this pathway.

Recent structural studies have elucidated the complex formed between MKK6 and p38α, revealing that the interaction involves multiple steps: initial docking via the kinase interaction motif (KIM), followed by formation of a face-to-face architecture that enables phosphorylation of the p38α activation loop . This model suggests that phosphorylation of MEK6 at Ser207 enables conformational changes necessary for efficient catalysis of p38 phosphorylation. Researchers can use MAP2K6 (Ab-207) Antibody to validate these models in cellular contexts.

What is the significance of MEK6 phosphorylation in vascular disease models?

Recent research has identified MAP2K6 as a potent genetic modifier of arterial rupture risk in vascular Ehlers-Danlos syndrome (vEDS) . In a mouse model of vEDS, mice on a 129 background showed higher levels of MEK6 activity compared to BL6 background mice, as evidenced by increased phosphorylation of p38α at Thr180/Tyr182 in aortic tissue . This increased MEK6 activity correlates with protection against aortic rupture.

Researchers studying vascular diseases can use MAP2K6 (Ab-207) Antibody to:

• Assess MEK6 activation status in various vascular tissues and disease models

• Investigate the correlation between MEK6 phosphorylation and vascular integrity

• Evaluate the potential protective effects of interventions that modulate MEK6 activity

• Study the downstream effects of MEK6 activation on protein phosphatase 1 (PP1) activity and PKC/ERK phosphorylation

This research area represents a promising avenue for developing therapeutic strategies to mitigate aortic rupture risk in vEDS patients.

What methodological approaches can be used to study the interaction between phosphorylated MEK6 and p38 MAPK?

Multiple complementary techniques can be employed to investigate the interaction between phosphorylated MEK6 and p38 MAPK:

Recent research has employed a combination of these techniques to characterize the MKK6-p38α complex, revealing the importance of the KIM-mediated interaction and subsequent face-to-face architecture that enables efficient phosphorylation of the p38α activation loop .

Why might I observe variable results with MAP2K6 (Ab-207) Antibody across different experimental conditions?

Variable results when using MAP2K6 (Ab-207) Antibody may stem from several factors:

• Phosphorylation dynamics: MEK6 phosphorylation is highly dynamic and responsive to cellular stress. Minor variations in cell culture conditions, handling stress, or time to lysis can significantly impact phosphorylation levels.

• Cross-reactivity: The antibody detects both phosphorylated MEK6 (Ser207) and MEK3 (Ser218) . Different cell types or conditions may alter the relative expression or phosphorylation of these proteins.

• Sample preparation: Inadequate preservation of phosphorylation states during sample preparation is a common issue. Ensure rapid sample processing and inclusion of appropriate phosphatase inhibitors in lysis buffers.

• Antibody dilution: The recommended dilution range (1:1000-1:6000) is broad . Titration experiments should be performed for each experimental system to determine optimal conditions.

• Detection method sensitivity: Different detection methods (chemiluminescence, fluorescence, etc.) have varying sensitivities that may affect signal detection, especially for low-abundance phosphoproteins.

What controls should I include when studying MEK6 phosphorylation in complex biological systems?

A robust experimental design should include the following controls:

• Positive controls: Samples treated with known activators of the p38 pathway, such as anisomycin, UV irradiation, or inflammatory cytokines .

• Negative controls: Samples treated with specific inhibitors of upstream kinases that phosphorylate MEK6, or MEK6 inhibitors if available.

• Phosphatase treatment control: A portion of the lysate treated with lambda phosphatase to demonstrate phospho-specificity of the antibody.

• Knockdown/knockout controls: When possible, include MEK6 knockdown/knockout samples to confirm antibody specificity.

• Total MEK6 detection: Parallel detection of total MEK6 protein to normalize phospho-specific signals and account for changes in protein expression.

• Loading controls: Standard loading controls (β-actin, GAPDH, etc.) to ensure equal protein loading across samples.

These controls will enhance data reliability and facilitate accurate interpretation of MEK6 phosphorylation dynamics in your experimental system.

How can MAP2K6 (Ab-207) Antibody be utilized in studying the dual phosphorylation mechanism of p38 MAPK?

The activation of p38 MAPK requires dual phosphorylation at Thr180 and Tyr182 residues, with MEK6 showing a preference for phosphorylating Tyr182 approximately four times faster than Thr180 . To investigate this sequential phosphorylation mechanism, researchers can:

• Design time-course experiments with very short intervals to capture the kinetics of p38 phosphorylation.

• Use phospho-specific antibodies that distinguish between mono-phosphorylated (either Thr180 or Tyr182) and dual-phosphorylated p38.

• Employ MAP2K6 (Ab-207) Antibody to correlate MEK6 activation status with the appearance of mono- and dual-phosphorylated p38 species.

• Develop in vitro kinase assays using recombinant MEK6 and p38, with phosphorylation site mutants to dissect the sequential nature of the process.

Understanding this mechanism has implications for designing targeted interventions that modulate specific aspects of p38 MAPK signaling in various disease contexts.

What is the relationship between MEK6 activation and protein phosphatase regulation in cellular stress responses?

Recent research has revealed that MEK6-activated p38 can increase the activation of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), which in turn dephosphorylate various substrates including protein kinase C (PKC) and extracellular signal-regulated kinase (ERK) . This regulatory circuit appears to be critical for protecting against vascular rupture in vEDS models.

Researchers interested in this area can use MAP2K6 (Ab-207) Antibody to:

• Correlate MEK6 phosphorylation status with PP1/PP2A activity under various stress conditions

• Investigate how modulation of MEK6 activation affects the phosphorylation state of downstream targets of PP1/PP2A

• Develop experimental systems to test the therapeutic potential of targeting this pathway in vascular diseases

This research direction highlights the complex interplay between kinase and phosphatase networks in maintaining cellular homeostasis during stress responses.